PetVivo Holdings, Inc. Announces Presentation of Clinical Study Results at the American College of Veterinary Surgeons Conference in Louisville, Kentucky
12 Ottobre 2023 - 3:55PM
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company” or
“PetVivo") an emerging biomedical device company focused on the
commercialization of innovative medical devices and therapeutics
for companion animals announced that the Company will be releasing
the results of a clinical study conducted by Ethos Veterinary
Health at the American College of Veterinary Surgeons (“ACVS”)
annual conference on the completion of a clinical study, which
examined the benefit and tolerability of an intra-articular
injection of a collagen-elastin biomaterial (i.e. Spryng™ with
OsteoCushion™ Technology) into the stifle joint of dogs with
suspected cruciate ligament rupture. Dr. Erik Kleeman, DVM will be
presenting the poster at ACVS.
“We were pleased to have the final results of
the Spryng clinical study offered in a poster presentation at the
ACVS annual conference as this data demonstrates the efficacy of
this product as an excellent, non-invasive alternative for patients
with cranial cruciate disease,” said John Lai, Chief Executive
Officer of PetVivo Holdings, Inc. “We continue to strive to provide
data demonstrating that Spryng is a viable tool to use in the
management of joint related afflictions and thereby enhancing the
lives of companion animals and their owners.”
Spryng is an injectable veterinary medical
device comprised of millions of micronized extracellular matrix
particles, which are derived from natural components, including
collagen and elastin. OsteoCushion Technology provides both
reinforcing natural joint support to augment and/or reinforce
missing and damaged cartilage, as well as delivers natural
scaffolding to help address tissue defects. These attributes offer
a great solution to manage lameness and joint afflictions, such as
osteoarthritis, for companion animals in a simple in-clinic
administration.
The dogs enrolled in this study had been
diagnosed with a partial or complete cranial cruciate ligament tear
(similar to an ACL tear in humans). The primary endpoint of the
study was to demonstrate whether there was a significant reduction
in pain after Spryng injection, as measured by the modified Glasgow
Composite Pain Scale; a significant reduction of pain by 25% or
greater would be considered a beneficial response. There were
significant improvements in all of the primary and secondary
clinical variables throughout the study period (pain, lameness,
quality of life scoring). In summary, this study demonstrates that
Spryng™ is a reasonable, non-invasive alternative for patients with
cranial cruciate disease (“CCD”) when patient and/or owner factors
preclude surgical intervention. To view the poster presentation and
a video interview of Dr. Kleeman discussing the clinical study
presented at the ACVS annual conference please visit the
following:
https://www.sprynghealth.com/acvs-2023-poster-presentation?fbclid=IwAR3VuoyNy8wdqFnnArkNsjI-HzTXtXo49jDI3WOn8-835jMBf5spy451O6E
About Ethos Veterinary
Health
Ethos Veterinary Health is a unique and
impactful science-focused animal health company with an emphasis on
collaboration, evidence-based decision making, a commitment to the
veterinary ethos, and cultivation of passion for what we do. The
Company operates 145 hospitals across the United States, with over
2000 Doctors of Veterinary Medicine, providing advanced medical
care for pets. Our approach includes a focus on transformative
science, continuous learning and growth for team members, and
innovation. For more information, visit www.ethosvet.com.
About PetVivo Holdings,
Inc.
PetVivo Holdings Inc. (NASDAQ: PETV & PETVW)
is an emerging biomedical device company currently focused on the
manufacturing, commercialization and licensing of innovative
medical devices and therapeutics for companion animals. The
Company's strategy is to leverage human therapies for the treatment
of companion animals in a capital and time efficient way. A key
component of this strategy is the accelerated timeline to revenues
for veterinary medical devices, which enter the market much earlier
than more stringently regulated pharmaceuticals and biologics.
PetVivo has a robust pipeline of products for
the treatment of animals and people. A portfolio of nineteen
patents protects the Company's biomaterials, products, production
processes and methods of use. The Company’s lead product SPRYNG™
with OsteoCushion™ technology, a veterinarian-administered,
intraarticular injection for the management of lameness and other
joint related afflictions, including osteoarthritis, in dogs and
horses, is currently available for commercial sale.
For more information about PetVivo Holdings,
Inc. and our revolutionary product, Spryng with OsteoCushion
Technology, please contact info1@petvivo.com or visit
https://petvivo.com/ or http://sprynghealth.com.
CONTACT:
John Lai, CEO PetVivo Holdings, Inc. Email:
info1@petvivo.com (952) 405-6216
Forward-Looking Statements:
The foregoing material may contain
“forward-looking statements” within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, each as amended. Forward-looking statements
include all statements that do not relate solely to historical or
current facts, including without limitation the Company’s proposed
development and commercial timelines, and can be identified by the
use of words such as “may,” “will,” “expect,” “project,”
“estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,”
“continue” or the negative versions of those words or other
comparable words. Forward-looking statements are not guarantees of
future actions or performance. These forward-looking statements are
based on information currently available to the Company and its
current plans or expectations and are subject to a number of
uncertainties and risks that could significantly affect current
plans. Risks concerning the Company’s business are described in
detail in the Company’s Annual Report on Form 10-K for the year
ended March 31, 2023 and other periodic and current reports filed
with the Securities and Exchange Commission. The Company is under
no obligation to, and expressly disclaims any such obligation to,
update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise.
Grafico Azioni PetVivo (NASDAQ:PETVW)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni PetVivo (NASDAQ:PETVW)
Storico
Da Mag 2023 a Mag 2024